{"gene":"PLTP","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1995,"finding":"Recombinant human and mouse PLTP expressed in BHK cells possesses both phospholipid transfer activity and HDL conversion activity, converting two distinct HDL subspecies (Lp(A-I) and Lp(A-I/A-II)) into larger and smaller particles in vitro.","method":"Eukaryotic cell expression of cDNA (BHK cells), in vitro HDL conversion assay with purified plasma-derived and recombinant PLTP","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution of both phospholipid transfer and HDL conversion with recombinant protein, replicated with plasma-derived PLTP","pmids":["7654777"],"is_preprint":false},{"year":1998,"finding":"PLTP binds to both apolipoprotein A-I and apoA-II; the PLTP-binding domain on apoA-I resides in the amino-terminal region (amino acids 27–141), as demonstrated by solid-phase ligand binding, ELISA displacement, and inhibition with anti-apoA-I monoclonal antibodies.","method":"Solid-phase ligand binding assay, ELISA with truncated recombinant apoA-I forms, apoA-I/apoA-II affinity chromatography, monoclonal antibody epitope mapping","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (affinity chromatography, ELISA, antibody inhibition) in a single focused study","pmids":["9469594"],"is_preprint":false},{"year":1999,"finding":"Structure of PLTP was modeled on the BPI X-ray structure, predicting a two-domain architecture with conserved lipid-binding pockets. Site-directed mutagenesis of N-terminal pocket residues abolished phospholipid transfer activity without impairing HDL binding, while C-terminal pocket mutations affected HDL association. A disulfide bridge between Cys146 and Cys185 is essential for structural integrity.","method":"Molecular modeling based on BPI X-ray structure, site-directed mutagenesis, transient expression in HeLa cells, phospholipid transfer activity assay, solid-phase HDL-binding assay","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis combined with functional assay and binding assay; multiple mutants tested in a single rigorous study","pmids":["10357844"],"is_preprint":false},{"year":1999,"finding":"PLTP has an inherent serine esterase-type protease activity: incubation with HDL3 or purified apoA-I causes proteolytic cleavage of apoA-I between residues Ala196 and Thr197 (generating a 23 kDa C-terminal fragment), inhibitable by APMSF and chymostatin. This activity was reproduced with recombinant PLTP from CHO and baculovirus systems.","method":"SDS-PAGE, Western blot, mass spectrometry, N-terminal sequencing, protease inhibitor experiments, in vitro incubation assay with purified plasma and recombinant PLTP","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — enzymatic activity confirmed by multiple methods (mass spec, sequencing, inhibitor profiling) with both plasma-derived and recombinant PLTP","pmids":["10191289"],"is_preprint":false},{"year":2000,"finding":"Phospholipid transfer is a prerequisite for PLTP-mediated HDL conversion: chemical modification of PLTP that reduces phospholipid transfer activity in parallel reduces HDL conversion; recombinant PLTP mutants defective in N-terminal lipid-binding pocket activity are unable to release apoA-I from HDL3 or generate prebeta-HDL particles.","method":"Chemical modification (DEPC, ethylmercurithiosalicylate), recombinant mutant protein production, native gradient gel electrophoresis, ultracentrifugation, crossed immunoelectrophoresis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — three independent analytical methods plus chemical modification and site-directed mutants establish causal link between transfer activity and HDL conversion","pmids":["11123937"],"is_preprint":false},{"year":2002,"finding":"Two forms of PLTP exist in human plasma: a high-activity form (HA-PLTP, ~160 kDa) associated with apoE but not apoA-I, and a low-activity form (LA-PLTP, ~520 kDa) complexed with apoA-I. LA-PLTP shows higher affinity for heparin-Sepharose than HA-PLTP; the model proposed is that nascent PLTP enters circulation as HA-PLTP and is transferred to apoA-I-containing HDL, becoming the LA-PLTP complex.","method":"Heparin-Sepharose chromatography, hydrophobic interaction chromatography, anti-PLTP immunoaffinity chromatography, hydroxylapatite chromatography, SDS-PAGE, Western blot, immunoprecipitation, gel filtration","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal biochemical fractionation and immunochemical methods in a single dedicated study","pmids":["11854286"],"is_preprint":false},{"year":2002,"finding":"PLTP is a direct transcriptional target of liver X receptor (LXR): LXR ligands induce PLTP 6-fold in murine and human macrophages, and two functional LXR response elements (one classic DR4, one novel IR1 identical to FXR response element) were identified and characterized in the proximal PLTP promoter.","method":"Affymetrix microarray, Northern blot, luciferase reporter assay with LXR response element mutations","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — functional LXRE characterized by mutagenesis in reporter assays, validated by Northern blot across two cell types","pmids":["12454263"],"is_preprint":false},{"year":2003,"finding":"PLTP secreted by HepG2 hepatoma cells co-elutes with apolipoprotein E (apoE) by size-exclusion chromatography and is retained on anti-apoE immunoaffinity columns; anti-apoE antibodies inhibit PLTP activity, indicating a functional interaction between PLTP and apoE in the high-activity form.","method":"Heparin-Sepharose affinity chromatography, size-exclusion chromatography, anti-apoE immunoaffinity chromatography, PLTP activity assay, antibody inhibition","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal immunoaffinity plus antibody inhibition of activity, multiple orthogonal methods","pmids":["12810820"],"is_preprint":false},{"year":2003,"finding":"Mast cell chymase proteolytically degrades PLTP into fragments (70, 52, 48, and 31 kDa), reducing its phospholipid transfer activity and ability to generate prebeta-HDL. Chymase also degrades pre-beta-HDL particles generated by PLTP, significantly inhibiting the high-affinity component of cholesterol efflux from macrophage foam cells.","method":"Immunoblot, in vitro chymase cleavage assay, phospholipid transfer activity assay, cholesterol efflux assay from macrophage foam cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro enzymatic cleavage mapped by immunoblot, functional consequences confirmed by activity assay and cholesterol efflux assay","pmids":["12531890"],"is_preprint":false},{"year":2004,"finding":"PLTP functions as a transfer factor for alpha-tocopherol (vitamin E) in the brain: PLTP-deficient mice show significant brain alpha-tocopherol depletion (-30%), accompanied by elevated lipofuscin, cholesterol oxides, and cellular peroxides, and increased anxiety behavior.","method":"PLTP knockout mouse model, alpha-tocopherol quantification, lipid peroxide assays, elevated plus-maze behavioral test","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function with multiple biochemical and behavioral readouts, dose-dependent in hetero- and homozygotes","pmids":["15576481"],"is_preprint":false},{"year":2005,"finding":"PLTP is synthesized and secreted as an active protein by neurons, microglia, and astrocytes in culture; exogenous recombinant PLTP added to primary human astrocytes significantly increases apoE secretion into conditioned medium, linking PLTP activity to apoE metabolism in the CNS.","method":"Western blot, phospholipid transfer activity assay in cell-conditioned medium, PLTP immunohistochemistry, exogenous recombinant PLTP addition to astrocyte cultures, apoE ELISA","journal":"Journal of neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct functional experiment (recombinant PLTP → apoE secretion) in a single lab with single cellular readout","pmids":["15795933"],"is_preprint":false},{"year":2008,"finding":"Phospholipid transfer activity of PLTP is essential for its atherogenic effects: mice expressing a transfer-inactive PLTP mutant (still able to associate with HDL) show no changes in HDL lipid levels, no stimulation of hepatic VLDL-TG secretion, and no increase in atherosclerotic lesion size, unlike mice expressing active PLTP.","method":"Transgenic mouse model expressing mutant PLTP (transfer-inactive), cholesterol-enriched diet atherosclerosis model, plasma lipid assays, hepatic VLDL secretion assay","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via mutagenesis in vivo, multiple metabolic and atherosclerosis endpoints compared between active and inactive transgene","pmids":["18711210"],"is_preprint":false},{"year":2008,"finding":"Acute elevation of plasma PLTP activity in LDL receptor knockout mice inhibits VLDL catabolism (at least partly by decreasing lipoprotein lipase activity), increases plasma VLDL levels, decreases HDL, and accelerates progression and destabilization of pre-existing atherosclerotic lesions.","method":"Conditional tetracycline-inducible PLTP transgenic mouse model, plasma lipid assays, VLDL secretion assay, lipoprotein lipase activity assay, atherosclerosis lesion analysis","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — inducible genetic model with multiple mechanistic readouts; lipoprotein lipase activity identified as downstream mechanism","pmids":["18421000"],"is_preprint":false},{"year":2009,"finding":"PLTP localizes to the nucleus of cells that constitutively express it and of PLTP-transfected cells; nuclear export of PLTP is CRM1-dependent (blocked by leptomycin B); secreted extracellular PLTP can re-enter cells and translocate to the nucleus; intranuclear PLTP retains phospholipid transfer activity.","method":"Subcellular fractionation, leptomycin B treatment, live-cell imaging, phospholipid transfer activity assay of nuclear fractions, transfection of CHO/BHK cells","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct localization experiment with functional consequence (nuclear PLTP is active), single lab","pmids":["19321130"],"is_preprint":false},{"year":2011,"finding":"PLTP activates the STAT3 anti-inflammatory pathway in macrophages via ABCA1: incubation with wild-type PLTP or a lipid-transfer-inactive PLTP mutant (M159E) both increase nuclear pSTAT3(Tyr705), and this effect is reversed by ABCA1 chemical inhibition (glyburide) or ABCA1 siRNA knockdown. PLTP also reduces nuclear NFκB p65 levels and pro-inflammatory cytokine secretion.","method":"Nuclear fractionation, Western blot for pSTAT3 and NFκB p65, ELISA for cytokines, ABCA1 inhibitor, ABCA1 siRNA, lipid-transfer-inactive PLTP mutant, differentiated THP1 cells and primary human macrophages","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic (siRNA) and pharmacological ABCA1 inhibition, inactive PLTP mutant used to dissociate lipid transfer from signaling, multiple orthogonal readouts","pmids":["21782857"],"is_preprint":false},{"year":2012,"finding":"Liver-specific PLTP expression (in PLTP-null background) dramatically increases plasma VLDL levels (non-HDL cholesterol 2.7-fold, apoB 2.2-fold) by increasing VLDL lipidation in hepatocyte microsomal lumina and VLDL secretion, without significantly affecting HDL.","method":"Adenovirus-mediated liver-specific PLTP expression in PLTP-null mice, VLDL secretion assay, hepatocyte microsomal lipidation assay, plasma lipoprotein profiling","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — tissue-specific rescue experiment with mechanistic readout (microsomal lipidation assay), clean PLTP-null background","pmids":["22367708"],"is_preprint":false},{"year":2014,"finding":"PLTP deficiency impairs blood-brain barrier integrity by increasing cerebrovascular oxidative stress (elevated ROS, 4-HNE, reduced SOD activity), leading to decreased expression of tight junction proteins occludin, ZO-1, and claudin-5; dietary vitamin E supplementation rescues BBB integrity, placing PLTP's vitamin E transfer activity upstream of BBB maintenance.","method":"PLTP knockout mice, in vivo multiphoton imaging, Evans blue assay, Western blot for tight junction proteins, ROS/lipid peroxidation assays, vitamin E dietary rescue","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic KO with multiple BBB readouts and mechanistic rescue by vitamin E, single lab","pmids":["24513285"],"is_preprint":false},{"year":2014,"finding":"Cathepsin G (a serine protease) cleaves and inactivates PLTP in the lung: PLTP activity in COPD bronchoalveolar lavage is reduced 80% due to cathepsin G-mediated degradation. PLTP siRNA silencing in mouse lungs increases ERK/NF-κB activation and inflammatory cell infiltration after LPS challenge, while recombinant PLTP protein counters these effects.","method":"Proteolytic cleavage assay, PLTP activity assay in BALF, PLTP siRNA in mouse lung (LPS model), recombinant PLTP administration, Western blot for ERK/NF-κB, ELISA for cytokines","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Moderate — protease identified biochemically, complementary gain-and-loss-of-function in vivo with multiple inflammatory readouts","pmids":["24532668"],"is_preprint":false},{"year":2015,"finding":"PLTP deficiency in an APP/PS1 Alzheimer's model accelerates memory dysfunction and increases Aβ peptides by enhancing the amyloidogenic APP processing pathway (increased β- and γ-secretase activity), and reduces BDNF levels; autophagic dysfunction is also observed in PLTP-deficient AD model mice.","method":"PLTP KO × APP/PS1ΔE9 double-mutant mice, Morris water maze, ELISA for Aβ40/42, Western blot for APP/secretase subunits, secretase activity assays","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic double-mutant model with mechanistic enzyme activity readout, single lab","pmids":["26160914"],"is_preprint":false},{"year":2018,"finding":"Electron microscopy reveals PLTP has a banana-shaped structure similar to CETP; PLTP penetrates into both HDL and LDL surfaces and forms a ternary PLTP–HDL–LDL complex, providing a structural basis for its phospholipid transfer mechanism between lipoproteins.","method":"Negative-stain electron microscopy, cryo-EM, single-particle analysis, ternary complex reconstitution","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — structural EM with reconstituted ternary complex, single lab without mutagenesis validation","pmids":["29883800"],"is_preprint":false},{"year":2018,"finding":"In rheumatoid arthritis fibroblast-like synoviocytes (FLS), both lipid-transfer-active and lipid-transfer-inactive recombinant PLTP increase pro-inflammatory cytokine production (IL-8, IL-6, VEGF, MMP3) and cell proliferation, and activate the STAT3 pathway via ABCA1; this pro-inflammatory effect is independent of PLTP's lipid transfer activity.","method":"Recombinant active and inactive PLTP treatment of FLS, ELISA for cytokines, [3H]-thymidine proliferation assay, ABCA1 flow cytometry, STAT3 Western blot","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — lipid-transfer-inactive PLTP mutant used to dissociate mechanism, multiple cytokine readouts; single lab","pmids":["29565987"],"is_preprint":false},{"year":2019,"finding":"PLTP deficiency protects mice from high-fat-diet-induced obesity and insulin resistance by enhancing insulin receptor and Akt phosphorylation in liver, adipose, and muscle; PLTP-deficient cells show increased GLUT4 at plasma membranes after insulin stimulation; mechanistically, PLTP deficiency reduces sphingomyelin and free cholesterol content in lipid rafts/plasma membranes, providing a molecular basis for improved insulin sensitivity.","method":"PLTP knockout mouse model, high-fat diet, glucose/insulin tolerance tests, Western blot for p-IR/p-Akt, plasma membrane GLUT4 fractionation, lipid raft lipid composition analysis","journal":"Biochimica et biophysica acta. Molecular and cell biology of lipids","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic KO with mechanistic lipid raft composition readout linking PLTP to membrane cholesterol and insulin signaling; single lab","pmids":["31220615"],"is_preprint":false},{"year":2020,"finding":"PLTP is a batokine secreted by brown adipose tissue (BAT): proteomics/transcriptomics in human thermogenic adipocytes identified PLTP; BAT-specific or systemic PLTP overexpression improves glucose tolerance and insulin sensitivity, increases energy expenditure, and reduces circulating cholesterol/phospholipids/sphingolipids. These effects are mediated by increased circulating bile acids, which enhance glucose uptake and thermogenesis in BAT.","method":"Proteomics and transcriptomics in human thermogenic adipocytes, BAT-specific and systemic PLTP overexpression in mice, glucose/insulin tolerance tests, bile acid measurements, energy expenditure measurements","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific overexpression identifies BAT as PLTP source; bile acid pathway proposed as mediator with supporting measurements, single lab","pmids":["32672883"],"is_preprint":false},{"year":2022,"finding":"PLTP is a p53 transcriptional target gene: three cancer-associated hypomorphic p53 variants show impaired PLTP transactivation by RNA-seq; enforced PLTP expression suppresses colony formation in human tumor cell lines and regulates ferroptosis sensitivity.","method":"RNA-seq in lymphoblastoid cell lines with p53 hypomorphs, colony formation assay with PLTP overexpression, ferroptosis sensitivity assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — transcriptional regulation by p53 confirmed by RNA-seq and functional overexpression; ferroptosis role demonstrated by single assay; single lab","pmids":["36309086"],"is_preprint":false},{"year":2025,"finding":"PLTP promotes M2 macrophage polarization in hepatocellular carcinoma by binding to aurora kinase A (AURKA) and p65, forming a ternary complex that induces p65 phosphorylation and activates NF-κB, upregulating IL-6, IL-8, and CSF-1; the PLTP inhibitor GMB-475 (binding PLTP's 25–245 AA domain) competitively disrupts this complex and reduces M2 infiltration in vivo.","method":"Co-immunoprecipitation, molecular docking, proteomics, Western blot for p-p65/NF-κB targets, ELISA for cytokines, GMB-475 treatment in orthotopic and Myc-driven HCC mouse models","journal":"Advanced science","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-IP identifies PLTP–AURKA–p65 complex; GMB-475 functional validation in vivo; single lab, preliminary mechanistic detail","pmids":["41391040"],"is_preprint":false},{"year":2025,"finding":"In diabetic retinopathy, DNMT3B-mediated DNA hypermethylation of the PLTP promoter suppresses PLTP expression; PLTP overexpression reverses high-glucose-induced impairment of endothelial cell migration and tube formation, and promotes AKT and GSK3β phosphorylation, placing PLTP upstream of the AKT/GSK3β signaling pathway in retinal vascular function.","method":"siRNA knockdown of DNMT3B, luciferase reporter assay, co-immunoprecipitation, transcriptome sequencing, GSK3β inhibitor, tube formation and migration assays in HRMECs, streptozotocin mouse model","journal":"Clinical epigenetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — DNMT3B identified as methylation writer by siRNA + reporter assay; PLTP-AKT/GSK3β pathway validated by multiple functional assays; single lab","pmids":["40380281"],"is_preprint":false},{"year":2012,"finding":"ApoA-I (and also apoE, apoA-II, apoA-IV but not immunoglobulins or BSA) enhances the phospholipid transfer activity of PLTP secreted from macrophage foam cells without affecting PLTP mass or secretion; apoA-I also protects PLTP from heat inactivation.","method":"THP-1 monocyte-derived macrophage foam cell model, PLTP activity assay in conditioned medium, PLTP ELISA, incubation with purified apolipoproteins and plasma-derived PLTP","journal":"Lipids in health and disease","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct in vitro biochemical experiment with isolated components; apolipoprotein specificity tested with multiple controls; single lab","pmids":["20534134"],"is_preprint":false},{"year":2021,"finding":"In vivo tracer/mass spectrometry studies show PLTP is secreted associated with medium and large HDL (alpha2, alpha1, alpha0) and is transferred from medium to larger HDL sizes during circulation, from which it is catabolized; this metabolic behavior is distinct from CETP and LCAT.","method":"In vivo stable-isotope tracer infusion, targeted mass spectrometry (Orbitrap Lumos), compartmental modeling across multiple HDL sizes in 6 human participants","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vivo human tracer study with compartmental modeling; small n=6; single lab but novel direct measurement of PLTP metabolism on HDL","pmids":["33351780"],"is_preprint":false}],"current_model":"PLTP is a secreted lipid-transfer glycoprotein with a two-domain, banana-shaped structure (modeled on BPI; confirmed by EM) that mediates phospholipid transfer between lipoproteins and remodels HDL by a mechanism requiring its N-terminal lipid-binding pocket and forming a transient PLTP–HDL–LDL ternary complex; phospholipid transfer is a prerequisite for HDL conversion and prebeta-HDL generation. PLTP circulates in two forms—a high-activity ~160 kDa complex associated with apoE and a low-activity ~520 kDa complex bound to apoA-I—and binds apoA-I at its N-terminal region (residues 27–141). Beyond lipid transfer, PLTP transfers alpha-tocopherol (vitamin E) to the brain and across the blood-brain barrier, transfers LPS to HDL for detoxification, and exerts ABCA1-dependent anti-inflammatory signaling in macrophages (activating STAT3, suppressing NF-κB) independent of its lipid transfer activity. PLTP is a direct LXR and p53 transcriptional target, undergoes CRM1-dependent nuclear export (with active intranuclear PLTP), and is cleaved/inactivated by cathepsin G and mast cell chymase. In the liver, PLTP drives VLDL lipidation and secretion; in brown adipose tissue it functions as a batokine that promotes bile acid-mediated glucose homeostasis; and in cancer cells it promotes M2 macrophage polarization via an AURKA–p65–NF-κB complex and suppresses tumor growth as a p53 target involved in ferroptosis regulation."},"narrative":{"mechanistic_narrative":"PLTP is a secreted lipid-transfer glycoprotein that remodels HDL and broadly governs plasma lipoprotein metabolism, transferring phospholipids between lipoproteins and converting HDL into larger and smaller subspecies while generating prebeta-HDL [PMID:7654777]. Structurally it adopts a two-domain, banana-shaped architecture modeled on BPI and visualized by electron microscopy, with an N-terminal lipid-binding pocket that executes transfer and a C-terminal pocket that mediates HDL association; an intramolecular disulfide (Cys146-Cys185) is required for structural integrity, and PLTP penetrates both HDL and LDL surfaces to form a transient ternary PLTP-HDL-LDL complex [PMID:10357844, PMID:29883800]. Phospholipid transfer is the obligate step driving HDL conversion and prebeta-HDL formation, as transfer-inactive mutants fail to release apoA-I or generate prebeta-HDL [PMID:11123937]. In plasma PLTP circulates as a high-activity ~160 kDa form associated with apoE and a low-activity ~520 kDa form complexed with apoA-I, binding apoA-I through its amino-terminal residues 27-141 [PMID:9469594, PMID:11854286, PMID:12810820]. The transfer activity is causally required for PLTP's metabolic effects in vivo: active PLTP stimulates hepatic VLDL lipidation and secretion and promotes atherosclerosis, whereas transfer-inactive PLTP does not [PMID:18711210, PMID:22367708]. Beyond lipid transfer, PLTP delivers alpha-tocopherol (vitamin E) to the brain, where its loss depletes brain vitamin E and compromises blood-brain barrier integrity through oxidative stress [PMID:15576481, PMID:24513285]. PLTP also exerts a lipid-transfer-independent, ABCA1-dependent anti-inflammatory program in macrophages, activating STAT3 and suppressing NF-kappaB [PMID:21782857]. Its expression is transcriptionally controlled, being a direct LXR and p53 target gene [PMID:12454263, PMID:36309086], and its activity is post-translationally limited by proteolytic inactivation through cathepsin G and mast cell chymase [PMID:12531890, PMID:24532668]. More recent work links PLTP to brown adipose tissue as a glucose-regulating batokine [PMID:32672883] and to tumor biology as a p53-responsive suppressor and modulator of macrophage polarization [PMID:36309086, PMID:41391040].","teleology":[{"year":1995,"claim":"Establishing that a single recombinant protein carries both phospholipid transfer and HDL conversion activity defined PLTP as the enzyme responsible for HDL particle remodeling.","evidence":"Recombinant human/mouse PLTP expressed in BHK cells, in vitro HDL conversion assays","pmids":["7654777"],"confidence":"High","gaps":["Did not establish whether the two activities are mechanistically coupled","No structural basis for activity"]},{"year":1998,"claim":"Mapping the apoA-I binding determinant to its N-terminal region (aa 27-141) identified the molecular contacts through which PLTP docks onto HDL apolipoproteins.","evidence":"Solid-phase ligand binding, ELISA with truncated apoA-I, antibody epitope mapping","pmids":["9469594"],"confidence":"High","gaps":["Did not define the reciprocal PLTP surface engaging apoA-I","Functional consequence of binding not yet linked to transfer"]},{"year":1999,"claim":"A BPI-based structural model plus mutagenesis resolved the division of labor between the N-terminal transfer pocket and C-terminal HDL-binding pocket and identified an essential stabilizing disulfide.","evidence":"Molecular modeling on BPI X-ray structure, site-directed mutagenesis, transient HeLa expression with transfer and HDL-binding assays","pmids":["10357844"],"confidence":"High","gaps":["Model not validated by direct PLTP structure determination","Catalytic mechanism of transfer unresolved"]},{"year":1999,"claim":"Detection of an intrinsic serine-esterase protease activity cleaving apoA-I raised the possibility that PLTP acts on lipoproteins beyond lipid transfer.","evidence":"SDS-PAGE, mass spectrometry, N-terminal sequencing, inhibitor profiling with plasma and recombinant PLTP","pmids":["10191289"],"confidence":"High","gaps":["Physiological relevance of the protease activity not established","Not reconciled with lipid-transfer mechanism"]},{"year":2000,"claim":"Showing that abolishing phospholipid transfer abolishes HDL conversion established transfer as the obligatory upstream step for prebeta-HDL generation.","evidence":"Chemical modification and N-terminal pocket mutants, native gel electrophoresis, ultracentrifugation, crossed immunoelectrophoresis","pmids":["11123937"],"confidence":"High","gaps":["Did not address transfer-independent functions later identified","In vitro only"]},{"year":2002,"claim":"Resolving plasma PLTP into apoE-associated high-activity and apoA-I-associated low-activity forms explained the heterogeneity of circulating PLTP activity.","evidence":"Multimodal chromatography, immunoprecipitation, gel filtration of human plasma","pmids":["11854286"],"confidence":"High","gaps":["Mechanism converting HA-PLTP to LA-PLTP inferred, not directly demonstrated","Structural basis of activity difference unknown"]},{"year":2002,"claim":"Identification of functional LXR response elements in the PLTP promoter placed PLTP under sterol-sensing transcriptional control in macrophages.","evidence":"Microarray, Northern blot, luciferase reporter assays with LXRE mutagenesis in murine and human macrophages","pmids":["12454263"],"confidence":"High","gaps":["In vivo relevance of LXR control to plasma PLTP not quantified","Other transcriptional inputs not addressed"]},{"year":2003,"claim":"Demonstrating apoE association of secreted PLTP and inhibition of activity by anti-apoE antibodies identified apoE as a functional partner of the high-activity form.","evidence":"HepG2 conditioned medium, anti-apoE immunoaffinity chromatography, antibody inhibition of activity","pmids":["12810820"],"confidence":"High","gaps":["Stoichiometry and binding interface with apoE undefined","How apoE enhances activity unresolved"]},{"year":2003,"claim":"Mast cell chymase degradation of PLTP and prebeta-HDL revealed a proteolytic mechanism limiting PLTP-driven cholesterol efflux.","evidence":"In vitro chymase cleavage, immunoblot fragment mapping, transfer activity and macrophage foam cell cholesterol efflux assays","pmids":["12531890"],"confidence":"High","gaps":["In vivo contribution of chymase to PLTP turnover not established","Cleavage sites not mapped"]},{"year":2004,"claim":"PLTP knockout mice with depleted brain vitamin E and oxidative damage extended PLTP function to alpha-tocopherol delivery in the CNS.","evidence":"PLTP KO mice, alpha-tocopherol and lipid peroxide quantification, behavioral testing","pmids":["15576481"],"confidence":"High","gaps":["Molecular mechanism of tocopherol transfer not dissected","Tissue route of delivery not defined"]},{"year":2005,"claim":"Demonstrating PLTP secretion by CNS cells and its stimulation of astrocyte apoE secretion linked PLTP to brain lipoprotein metabolism.","evidence":"Western blot, activity assays in conditioned medium, immunohistochemistry, exogenous PLTP addition with apoE ELISA","pmids":["15795933"],"confidence":"Medium","gaps":["Single readout in one lab","Mechanism by which PLTP increases apoE secretion unknown"]},{"year":2008,"claim":"Transgenic expression of transfer-inactive PLTP showed lipid transfer is necessary for PLTP's effects on HDL, VLDL secretion, and atherosclerosis in vivo.","evidence":"Transgenic mice expressing transfer-inactive PLTP, atherosclerosis diet model, plasma lipid and hepatic VLDL assays","pmids":["18711210"],"confidence":"High","gaps":["Did not address transfer-independent signaling functions","Mechanism of VLDL stimulation not yet localized to hepatocyte"]},{"year":2008,"claim":"Acute PLTP elevation worsening lipoprotein profiles via reduced lipoprotein lipase activity identified a downstream metabolic mechanism for PLTP's atherogenicity.","evidence":"Inducible PLTP transgenic LDLR-KO mice, VLDL secretion, lipoprotein lipase activity, lesion analysis","pmids":["18421000"],"confidence":"High","gaps":["How PLTP reduces LPL activity unresolved","Reversibility not tested"]},{"year":2009,"claim":"Discovery of CRM1-dependent nuclear export and active intranuclear PLTP raised the prospect of a non-secretory intracellular role.","evidence":"Subcellular fractionation, leptomycin B, live imaging, activity assay of nuclear fractions","pmids":["19321130"],"confidence":"Medium","gaps":["Nuclear substrates or functions not identified","Single lab"]},{"year":2011,"claim":"Using a lipid-transfer-inactive mutant and ABCA1 loss-of-function established a transfer-independent anti-inflammatory STAT3/NF-kappaB signaling function in macrophages.","evidence":"Nuclear fractionation/Western blot, ABCA1 siRNA and glyburide, inactive PLTP mutant in THP1 and primary macrophages","pmids":["21782857"],"confidence":"High","gaps":["Direct PLTP-ABCA1 interaction not demonstrated","Receptor-level mechanism of STAT3 activation unknown"]},{"year":2012,"claim":"Liver-specific PLTP expression localized the VLDL-stimulating activity to hepatocyte microsomal lipidation, defining PLTP's role in VLDL assembly.","evidence":"Adenoviral liver-specific PLTP in PLTP-null mice, microsomal lipidation and VLDL secretion assays","pmids":["22367708"],"confidence":"High","gaps":["Intracellular site of PLTP action within the secretory pathway not pinpointed","Relationship to circulating PLTP unclear"]},{"year":2012,"claim":"Demonstrating apolipoprotein-specific enhancement of PLTP activity clarified how HDL apolipoproteins modulate and stabilize secreted PLTP.","evidence":"THP-1 foam cell conditioned medium, activity assays and heat-inactivation protection with purified apolipoproteins","pmids":["20534134"],"confidence":"Medium","gaps":["Structural basis of activity enhancement not defined","Single lab"]},{"year":2014,"claim":"Linking PLTP loss to BBB breakdown reversible by vitamin E placed PLTP's tocopherol transfer upstream of cerebrovascular integrity.","evidence":"PLTP KO mice, multiphoton imaging, Evans blue, tight junction Western blots, vitamin E rescue","pmids":["24513285"],"confidence":"Medium","gaps":["Cellular target of oxidative stress not identified","Single lab"]},{"year":2014,"claim":"Identifying cathepsin G as a PLTP-inactivating protease in lung and showing PLTP restrains LPS-induced inflammation extended proteolytic regulation and anti-inflammatory roles to the airway.","evidence":"Proteolytic cleavage assays, BALF activity, lung PLTP siRNA and recombinant PLTP in LPS model with ERK/NF-kappaB readouts","pmids":["24532668"],"confidence":"High","gaps":["Cleavage sites not mapped","Relationship to chymase-mediated cleavage not compared"]},{"year":2015,"claim":"PLTP deficiency accelerating amyloid pathology in an Alzheimer's model implicated PLTP in APP processing and neuronal homeostasis.","evidence":"PLTP KO x APP/PS1 mice, behavioral tests, Abeta ELISA, secretase activity assays","pmids":["26160914"],"confidence":"Medium","gaps":["Mechanism connecting PLTP to secretase activity unknown","Single lab"]},{"year":2018,"claim":"Electron microscopy of PLTP and a reconstituted ternary complex provided the structural basis for inter-lipoprotein phospholipid transfer.","evidence":"Negative-stain and cryo-EM single-particle analysis, ternary PLTP-HDL-LDL complex reconstitution","pmids":["29883800"],"confidence":"Medium","gaps":["No atomic-resolution structure or mutagenesis validation","Single lab"]},{"year":2018,"claim":"Showing transfer-independent pro-inflammatory STAT3/ABCA1 signaling in synoviocytes generalized PLTP's signaling function beyond macrophages and beyond a purely protective role.","evidence":"Active and inactive recombinant PLTP on fibroblast-like synoviocytes, cytokine ELISA, proliferation and STAT3 assays","pmids":["29565987"],"confidence":"Medium","gaps":["Context-dependence of pro- vs anti-inflammatory STAT3 outcome unexplained","Single lab"]},{"year":2019,"claim":"PLTP deficiency improving insulin sensitivity via reduced membrane sphingomyelin/cholesterol linked PLTP to lipid raft composition and insulin signaling.","evidence":"PLTP KO mice on high-fat diet, glucose/insulin tests, p-IR/p-Akt and GLUT4 fractionation, lipid raft composition analysis","pmids":["31220615"],"confidence":"Medium","gaps":["Direct PLTP action on membrane lipids not demonstrated in situ","Single lab"]},{"year":2020,"claim":"Identifying PLTP as a brown adipose batokine acting through circulating bile acids defined a new endocrine role in glucose homeostasis and thermogenesis.","evidence":"Human thermogenic adipocyte proteomics/transcriptomics, BAT-specific and systemic PLTP overexpression, glucose/bile acid/energy expenditure measurements","pmids":["32672883"],"confidence":"Medium","gaps":["Mechanism by which PLTP raises bile acids unresolved","Single lab"]},{"year":2021,"claim":"Human in vivo tracer studies established that PLTP is secreted on medium/large HDL and follows a catabolic route distinct from CETP and LCAT.","evidence":"Stable-isotope tracer infusion, targeted mass spectrometry and compartmental modeling in 6 participants","pmids":["33351780"],"confidence":"Medium","gaps":["Small sample size","Molecular determinants of HDL-size association not defined"]},{"year":2022,"claim":"Establishing PLTP as a p53 transcriptional target with tumor-suppressive and ferroptosis-modulating activity connected PLTP to the p53 stress-response network.","evidence":"RNA-seq in p53-hypomorph lymphoblastoid lines, colony formation and ferroptosis assays with PLTP overexpression","pmids":["36309086"],"confidence":"Medium","gaps":["Mechanism linking PLTP to ferroptosis not defined","Single ferroptosis assay"]},{"year":2025,"claim":"Identifying a PLTP-AURKA-p65 complex driving NF-kappaB-dependent M2 macrophage polarization revealed a protein-protein-interaction mechanism in hepatocellular carcinoma.","evidence":"Co-IP, docking, proteomics, p-p65 Western blots, cytokine ELISA, GMB-475 inhibitor in orthotopic and Myc-driven HCC models","pmids":["41391040"],"confidence":"Medium","gaps":["Reciprocal validation and binding interface incompletely defined","Single lab"]},{"year":2025,"claim":"Showing DNMT3B-mediated promoter hypermethylation silences PLTP and that PLTP drives AKT/GSK3beta signaling defined epigenetic control and a vascular signaling axis in diabetic retinopathy.","evidence":"DNMT3B siRNA, luciferase reporter, co-IP, transcriptomics, migration/tube formation assays in HRMECs, STZ mouse model","pmids":["40380281"],"confidence":"Medium","gaps":["Direct PLTP receptor/effector for AKT activation unidentified","Single lab"]},{"year":null,"claim":"How PLTP's lipid-transfer-independent signaling functions are physically transduced — including the receptor or membrane events linking PLTP to ABCA1/STAT3, the basis of intranuclear activity, and the determinants of its context-dependent pro- versus anti-inflammatory output — remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined receptor for PLTP signaling","Nuclear function and substrates undefined","Atomic-resolution structure with mutational validation lacking"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[0,4,19]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,9,19]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[14,20]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,5,7,27]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[13]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,11,15]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[14,17,20,24]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,24,25]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,23,25]}],"complexes":["PLTP-HDL-LDL ternary complex","PLTP-AURKA-p65 complex","high-activity PLTP-apoE complex","low-activity PLTP-apoA-I complex"],"partners":["APOA1","APOE","APOA2","ABCA1","AURKA","RELA","STAT3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P55058","full_name":"Phospholipid transfer protein","aliases":["Lipid transfer protein II"],"length_aa":493,"mass_kda":54.7,"function":"Mediates the transfer of phospholipids and free cholesterol from triglyceride-rich lipoproteins (low density lipoproteins or LDL and very low density lipoproteins or VLDL) into high-density lipoproteins (HDL) as well as the exchange of phospholipids between triglyceride-rich lipoproteins themselves (PubMed:11013307, PubMed:19321130, PubMed:21515415, PubMed:29883800, PubMed:7654777, PubMed:9132017). Facilitates the transfer of a spectrum of different lipid molecules, including diacylglycerol, phosphatidic acid, sphingomyelin, phosphatidylcholine, phosphatidylinositol, phosphatidylglycerol, cerebroside and phosphatidyl ethanolamine (PubMed:9132017). Plays an important role in HDL remodeling which involves modulating the size and composition of HDL (PubMed:29883800). Also plays a key role in the uptake of cholesterol from peripheral cells and tissues that is subsequently transported to the liver for degradation and excretion (PubMed:21736953). Two distinct forms of PLTP exist in plasma: an active form that can transfer phosphatidylcholine from phospholipid vesicles to HDL, and an inactive form that lacks this capability (PubMed:11013307)","subcellular_location":"Secreted; Nucleus","url":"https://www.uniprot.org/uniprotkb/P55058/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PLTP","classification":"Not Classified","n_dependent_lines":8,"n_total_lines":1208,"dependency_fraction":0.006622516556291391},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PLTP","total_profiled":1310},"omim":[{"mim_id":"615334","title":"CERAMIDE SYNTHASE 4; CERS4","url":"https://www.omim.org/entry/615334"},{"mim_id":"609708","title":"LIPOPROTEIN LIPASE; LPL","url":"https://www.omim.org/entry/609708"},{"mim_id":"607412","title":"BPI FOLD-CONTAINING PROTEIN, FAMILY A, MEMBER 1; BPIFA1","url":"https://www.omim.org/entry/607412"},{"mim_id":"606613","title":"HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 1; HDLCQ1","url":"https://www.omim.org/entry/606613"},{"mim_id":"602274","title":"UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 2; GALNT2","url":"https://www.omim.org/entry/602274"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PLTP"},"hgnc":{"alias_symbol":["BPIFE"],"prev_symbol":[]},"alphafold":{"accession":"P55058","domains":[{"cath_id":"3.15.20.10","chopping":"19-29_209-286_439-475","consensus_level":"medium","plddt":95.4731,"start":19,"end":475},{"cath_id":"3.15.10.10","chopping":"50-202","consensus_level":"high","plddt":89.4346,"start":50,"end":202},{"cath_id":"3.15.20.10","chopping":"287-427","consensus_level":"medium","plddt":92.1811,"start":287,"end":427}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P55058","model_url":"https://alphafold.ebi.ac.uk/files/AF-P55058-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P55058-F1-predicted_aligned_error_v6.png","plddt_mean":89.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PLTP","jax_strain_url":"https://www.jax.org/strain/search?query=PLTP"},"sequence":{"accession":"P55058","fasta_url":"https://rest.uniprot.org/uniprotkb/P55058.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P55058/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P55058"}},"corpus_meta":[{"pmid":"11254896","id":"PMC_11254896","title":"The impact of phospholipid transfer protein (PLTP) on HDL metabolism.","date":"2001","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/11254896","citation_count":190,"is_preprint":false},{"pmid":"7654777","id":"PMC_7654777","title":"Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspecies.","date":"1995","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/7654777","citation_count":120,"is_preprint":false},{"pmid":"12454263","id":"PMC_12454263","title":"Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors.","date":"2002","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12454263","citation_count":109,"is_preprint":false},{"pmid":"15576481","id":"PMC_15576481","title":"Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice.","date":"2004","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/15576481","citation_count":93,"is_preprint":false},{"pmid":"11854286","id":"PMC_11854286","title":"Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP).","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11854286","citation_count":69,"is_preprint":false},{"pmid":"21787334","id":"PMC_21787334","title":"Plasma PLTP (phospholipid-transfer protein): an emerging role in 'reverse lipopolysaccharide transport' and innate immunity.","date":"2011","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/21787334","citation_count":61,"is_preprint":false},{"pmid":"10924722","id":"PMC_10924722","title":"Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity.","date":"2000","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/10924722","citation_count":61,"is_preprint":false},{"pmid":"9441745","id":"PMC_9441745","title":"Similar organization of the lipopolysaccharide-binding protein (LBP) and phospholipid transfer protein (PLTP) genes suggests a common gene family of lipid-binding proteins.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9441745","citation_count":58,"is_preprint":false},{"pmid":"15258196","id":"PMC_15258196","title":"PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15258196","citation_count":58,"is_preprint":false},{"pmid":"19413703","id":"PMC_19413703","title":"Plasma phospholipid transfer protein (PLTP): review of an emerging cardiometabolic risk factor.","date":"2009","source":"Obesity reviews : an official journal of the International Association for the Study of Obesity","url":"https://pubmed.ncbi.nlm.nih.gov/19413703","citation_count":57,"is_preprint":false},{"pmid":"12671035","id":"PMC_12671035","title":"Widespread distribution of PLTP in human CNS: evidence for PLTP synthesis by glia and neurons, and increased levels in Alzheimer's disease.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12671035","citation_count":56,"is_preprint":false},{"pmid":"12810820","id":"PMC_12810820","title":"PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12810820","citation_count":53,"is_preprint":false},{"pmid":"15863365","id":"PMC_15863365","title":"Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15863365","citation_count":50,"is_preprint":false},{"pmid":"10357844","id":"PMC_10357844","title":"Structure and phospholipid transfer activity of human PLTP: analysis by molecular modeling and site-directed mutagenesis.","date":"1999","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10357844","citation_count":49,"is_preprint":false},{"pmid":"16960448","id":"PMC_16960448","title":"Statins of different brain penetrability differentially affect CSF PLTP activity.","date":"2006","source":"Dementia and geriatric cognitive disorders","url":"https://pubmed.ncbi.nlm.nih.gov/16960448","citation_count":49,"is_preprint":false},{"pmid":"32672883","id":"PMC_32672883","title":"The regulation of glucose and lipid homeostasis via PLTP as a mediator of BAT-liver communication.","date":"2020","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/32672883","citation_count":48,"is_preprint":false},{"pmid":"9469594","id":"PMC_9469594","title":"Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I.","date":"1998","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/9469594","citation_count":48,"is_preprint":false},{"pmid":"10681407","id":"PMC_10681407","title":"PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance.","date":"2000","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10681407","citation_count":48,"is_preprint":false},{"pmid":"21782857","id":"PMC_21782857","title":"PLTP regulates STAT3 and NFκB in differentiated THP1 cells and human monocyte-derived macrophages.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21782857","citation_count":47,"is_preprint":false},{"pmid":"15795933","id":"PMC_15795933","title":"Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro.","date":"2005","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/15795933","citation_count":43,"is_preprint":false},{"pmid":"22367708","id":"PMC_22367708","title":"Liver phospholipid transfer protein (PLTP) expression with a PLTP-null background promotes very low-density lipoprotein production in mice.","date":"2012","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22367708","citation_count":42,"is_preprint":false},{"pmid":"17553507","id":"PMC_17553507","title":"Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis.","date":"2007","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/17553507","citation_count":42,"is_preprint":false},{"pmid":"11123937","id":"PMC_11123937","title":"Phospholipid transfer is a prerequisite for PLTP-mediated HDL conversion.","date":"2000","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11123937","citation_count":42,"is_preprint":false},{"pmid":"22897926","id":"PMC_22897926","title":"The impact of phospholipid transfer protein (PLTP) on lipoprotein metabolism.","date":"2012","source":"Nutrition & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22897926","citation_count":42,"is_preprint":false},{"pmid":"12893687","id":"PMC_12893687","title":"Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12893687","citation_count":40,"is_preprint":false},{"pmid":"23303044","id":"PMC_23303044","title":"Increased amyloid-β peptide-induced memory deficits in phospholipid transfer protein (PLTP) gene knockout mice.","date":"2012","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23303044","citation_count":37,"is_preprint":false},{"pmid":"24513285","id":"PMC_24513285","title":"Phospholipid transfer protein (PLTP) deficiency impaired blood-brain barrier integrity by increasing cerebrovascular oxidative stress.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/24513285","citation_count":36,"is_preprint":false},{"pmid":"11566452","id":"PMC_11566452","title":"The role of plasma phospholipid transfer protein (PLTP) in HDL remodeling in acute-phase patients.","date":"2001","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11566452","citation_count":35,"is_preprint":false},{"pmid":"19100548","id":"PMC_19100548","title":"Elevation of systemic PLTP, but not macrophage-PLTP, impairs macrophage reverse cholesterol transport in transgenic mice.","date":"2008","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19100548","citation_count":35,"is_preprint":false},{"pmid":"24532668","id":"PMC_24532668","title":"Cathepsin G degradation of phospholipid transfer protein (PLTP) augments pulmonary inflammation.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24532668","citation_count":33,"is_preprint":false},{"pmid":"12754275","id":"PMC_12754275","title":"Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12754275","citation_count":33,"is_preprint":false},{"pmid":"34974028","id":"PMC_34974028","title":"New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis.","date":"2021","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34974028","citation_count":32,"is_preprint":false},{"pmid":"36309086","id":"PMC_36309086","title":"PLTP is a p53 target gene with roles in cancer growth suppression and ferroptosis.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36309086","citation_count":32,"is_preprint":false},{"pmid":"29558025","id":"PMC_29558025","title":"Plasma lipid transfer proteins: The role of PLTP and CETP in atherogenesis.","date":"2018","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/29558025","citation_count":31,"is_preprint":false},{"pmid":"28596518","id":"PMC_28596518","title":"Recombinant human plasma phospholipid transfer protein (PLTP) to prevent bacterial growth and to treat sepsis.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28596518","citation_count":31,"is_preprint":false},{"pmid":"11254899","id":"PMC_11254899","title":"Acute-phase HDL in phospholipid transfer protein (PLTP)-mediated HDL conversion.","date":"2001","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/11254899","citation_count":31,"is_preprint":false},{"pmid":"10191289","id":"PMC_10191289","title":"Phospholipid transfer protein (PLTP) causes proteolytic cleavage of apolipoprotein A-I.","date":"1999","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10191289","citation_count":30,"is_preprint":false},{"pmid":"12837855","id":"PMC_12837855","title":"PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12837855","citation_count":29,"is_preprint":false},{"pmid":"11290460","id":"PMC_11290460","title":"Dynamic changes in mouse lipoproteins induced by transiently expressed human phospholipid transfer protein (PLTP): importance of PLTP in prebeta-HDL generation.","date":"2001","source":"Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11290460","citation_count":29,"is_preprint":false},{"pmid":"10487493","id":"PMC_10487493","title":"Serum phospholipid transfer protein activity and genetic variation of the PLTP gene.","date":"1999","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/10487493","citation_count":26,"is_preprint":false},{"pmid":"18421000","id":"PMC_18421000","title":"Acute elevation of plasma PLTP activity strongly increases pre-existing atherosclerosis.","date":"2008","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/18421000","citation_count":25,"is_preprint":false},{"pmid":"16388083","id":"PMC_16388083","title":"Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemia.","date":"2005","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16388083","citation_count":25,"is_preprint":false},{"pmid":"26160914","id":"PMC_26160914","title":"Phospholipid transfer protein (PLTP) deficiency accelerates memory dysfunction through altering amyloid precursor protein (APP) processing in a mouse model of Alzheimer's disease.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26160914","citation_count":24,"is_preprint":false},{"pmid":"12531890","id":"PMC_12531890","title":"Degradation of phospholipid transfer protein (PLTP) and PLTP-generated pre-beta-high density lipoprotein by mast cell chymase impairs high affinity efflux of cholesterol from macrophage foam cells.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12531890","citation_count":24,"is_preprint":false},{"pmid":"11861670","id":"PMC_11861670","title":"Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement.","date":"2002","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/11861670","citation_count":23,"is_preprint":false},{"pmid":"17928634","id":"PMC_17928634","title":"Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency.","date":"2007","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/17928634","citation_count":22,"is_preprint":false},{"pmid":"12177167","id":"PMC_12177167","title":"Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinemia.","date":"2002","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12177167","citation_count":22,"is_preprint":false},{"pmid":"29883800","id":"PMC_29883800","title":"Structural basis of the lipid transfer mechanism of phospholipid transfer protein (PLTP).","date":"2018","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/29883800","citation_count":22,"is_preprint":false},{"pmid":"25710294","id":"PMC_25710294","title":"Elevated baseline plasma phospholipid protein (PLTP) levels are an independent predictor of long-term all-cause mortality in patients with diabetes mellitus and known or suspected coronary artery disease.","date":"2015","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/25710294","citation_count":22,"is_preprint":false},{"pmid":"19446293","id":"PMC_19446293","title":"Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography.","date":"2009","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/19446293","citation_count":22,"is_preprint":false},{"pmid":"22034170","id":"PMC_22034170","title":"Ox-LDL-induced TGF-β1 production in human alveolar epithelial cells: involvement of the Ras/ERK/PLTP pathway.","date":"2012","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22034170","citation_count":21,"is_preprint":false},{"pmid":"26258626","id":"PMC_26258626","title":"Cigarette smoke extract induces apoptosis of rat alveolar Type II cells via the PLTP/TGF-β1/Smad2 pathway.","date":"2015","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26258626","citation_count":21,"is_preprint":false},{"pmid":"29565987","id":"PMC_29565987","title":"PhosphoLipid transfer protein (PLTP) exerts a direct pro-inflammatory effect on rheumatoid arthritis (RA) fibroblasts-like-synoviocytes (FLS) independently of its lipid transfer activity.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/29565987","citation_count":21,"is_preprint":false},{"pmid":"17761633","id":"PMC_17761633","title":"Atherogenic, enlarged, and dysfunctional HDL in human PLTP/apoA-I double transgenic mice.","date":"2007","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/17761633","citation_count":21,"is_preprint":false},{"pmid":"9555005","id":"PMC_9555005","title":"Oxidative modification of HDL3 in vitro and its effect on PLTP-mediated phospholipid transfer.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9555005","citation_count":20,"is_preprint":false},{"pmid":"19948027","id":"PMC_19948027","title":"Plasma PLTP activity is inversely associated with HDL-C levels.","date":"2009","source":"Nutrition & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19948027","citation_count":19,"is_preprint":false},{"pmid":"33351780","id":"PMC_33351780","title":"Metabolism of PLTP, CETP, and LCAT on multiple HDL sizes using the Orbitrap Fusion Lumos.","date":"2021","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33351780","citation_count":18,"is_preprint":false},{"pmid":"15832314","id":"PMC_15832314","title":"Phospholipid transfer protein (PLTP) mRNA expression is stimulated by developing embryos in the oviduct.","date":"2005","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15832314","citation_count":18,"is_preprint":false},{"pmid":"26320740","id":"PMC_26320740","title":"Plasma phospholipid transfer protein (PLTP) modulates adaptive immune functions through alternation of T helper cell polarization.","date":"2015","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26320740","citation_count":18,"is_preprint":false},{"pmid":"15365582","id":"PMC_15365582","title":"Effects of weight loss on PLTP activity and HDL particle size.","date":"2004","source":"International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity","url":"https://pubmed.ncbi.nlm.nih.gov/15365582","citation_count":18,"is_preprint":false},{"pmid":"18826383","id":"PMC_18826383","title":"SAA and PLTP activity in plasma of periodontal patients before and after full-mouth tooth extraction.","date":"2008","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/18826383","citation_count":16,"is_preprint":false},{"pmid":"19321130","id":"PMC_19321130","title":"PLTP is present in the nucleus, and its nuclear export is CRM1-dependent.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19321130","citation_count":15,"is_preprint":false},{"pmid":"21973210","id":"PMC_21973210","title":"Type 2 diabetes mellitus interacts with obesity and common variations in PLTP to affect plasma phospholipid transfer protein activity.","date":"2011","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21973210","citation_count":15,"is_preprint":false},{"pmid":"24121956","id":"PMC_24121956","title":"PLTP deficiency impairs learning and memory capabilities partially due to alteration of amyloid-β metabolism in old mice.","date":"2014","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/24121956","citation_count":15,"is_preprint":false},{"pmid":"31220615","id":"PMC_31220615","title":"Phospholipid transfer protein (PLTP) deficiency attenuates high fat diet induced obesity and insulin resistance.","date":"2019","source":"Biochimica et biophysica acta. Molecular and cell biology of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/31220615","citation_count":14,"is_preprint":false},{"pmid":"26009633","id":"PMC_26009633","title":"PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity.","date":"2015","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/26009633","citation_count":14,"is_preprint":false},{"pmid":"11324722","id":"PMC_11324722","title":"Differential display reveals downregulation of the phospholipid transfer protein (PLTP) at the mRNA level in brains of patients with Down syndrome.","date":"2001","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11324722","citation_count":13,"is_preprint":false},{"pmid":"18711210","id":"PMC_18711210","title":"Plasma phospholipid transfer activity is essential for increased atherogenesis in PLTP transgenic mice: a mutation-inactivation study.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18711210","citation_count":13,"is_preprint":false},{"pmid":"36362012","id":"PMC_36362012","title":"Increased Weight Gain and Insulin Resistance in HF-Fed PLTP Deficient Mice Is Related to Altered Inflammatory Response and Plasma Transport of Gut-Derived LPS.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36362012","citation_count":12,"is_preprint":false},{"pmid":"29731975","id":"PMC_29731975","title":"Deletion of plasma Phospholipid Transfer Protein (PLTP) increases microglial phagocytosis and reduces cerebral amyloid-β deposition in the J20 mouse model of Alzheimer's disease.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29731975","citation_count":12,"is_preprint":false},{"pmid":"10356658","id":"PMC_10356658","title":"Introduction of the human PLTP transgene suppresses the atherogenic diet-induced increase in plasma phospholipid transfer activity in C57BL/6 mice.","date":"1999","source":"International journal of clinical & laboratory research","url":"https://pubmed.ncbi.nlm.nih.gov/10356658","citation_count":12,"is_preprint":false},{"pmid":"12117557","id":"PMC_12117557","title":"Role of hepatic lipase and scavenger receptor BI in clearing phospholipid/free cholesterol-rich lipoproteins in PLTP-deficient mice.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12117557","citation_count":10,"is_preprint":false},{"pmid":"20534134","id":"PMC_20534134","title":"Human apoA-I increases macrophage foam cell derived PLTP activity without affecting the PLTP mass.","date":"2010","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/20534134","citation_count":9,"is_preprint":false},{"pmid":"23545183","id":"PMC_23545183","title":"High PLTP activity is associated with depressed left ventricular systolic function.","date":"2013","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/23545183","citation_count":9,"is_preprint":false},{"pmid":"23313246","id":"PMC_23313246","title":"Elevated expression of PLTP is atherogenic in apolipoprotein E deficient mice.","date":"2012","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/23313246","citation_count":8,"is_preprint":false},{"pmid":"21514421","id":"PMC_21514421","title":"Dry eye symptoms are increased in mice deficient in phospholipid transfer protein (PLTP).","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21514421","citation_count":8,"is_preprint":false},{"pmid":"21303701","id":"PMC_21303701","title":"Different phospholipid transfer protein complexes contribute to the variation in plasma PLTP specific activity.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21303701","citation_count":7,"is_preprint":false},{"pmid":"28012603","id":"PMC_28012603","title":"Overexpressed PLTP in macrophage may promote cholesterol accumulation by prolonged endoplasmic reticulum stress.","date":"2016","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/28012603","citation_count":7,"is_preprint":false},{"pmid":"20667734","id":"PMC_20667734","title":"Synthesis of a series of novel 2,4,5-trisubstituted selenazole compounds as potential PLTP inhibitors.","date":"2010","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/20667734","citation_count":7,"is_preprint":false},{"pmid":"20714154","id":"PMC_20714154","title":"Genetic association between PLTP gene polymorphisms and Alzheimer's disease in a Japanese population.","date":"2010","source":"Dementia and geriatric cognitive disorders","url":"https://pubmed.ncbi.nlm.nih.gov/20714154","citation_count":6,"is_preprint":false},{"pmid":"17437182","id":"PMC_17437182","title":"Inducible expression of phospholipid transfer protein (PLTP) in transgenic mice: acute effects of PLTP on lipoprotein metabolism.","date":"2007","source":"Transgenic research","url":"https://pubmed.ncbi.nlm.nih.gov/17437182","citation_count":6,"is_preprint":false},{"pmid":"19422933","id":"PMC_19422933","title":"Reduction of HDL levels lowers plasma PLTP and affects its distribution among lipoproteins in mice.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19422933","citation_count":4,"is_preprint":false},{"pmid":"30090492","id":"PMC_30090492","title":"Cigarette smoke extract induces the epithelial-to-mesenchymal transition via the PLTP/TGF-β1/Smad2 pathway in RLE-6TN cells.","date":"2016","source":"Toxicology research","url":"https://pubmed.ncbi.nlm.nih.gov/30090492","citation_count":4,"is_preprint":false},{"pmid":"40380281","id":"PMC_40380281","title":"DNA hypermethylation of PLTP mediated by DNMT3B aggravates vascular dysfunction in diabetic retinopathy via the AKT/GSK3β signaling pathway.","date":"2025","source":"Clinical epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/40380281","citation_count":3,"is_preprint":false},{"pmid":"35341274","id":"PMC_35341274","title":"AGTR1, PLTP, and SCG2 associated with immune genes and immune cell infiltration in calcific aortic valve stenosis: analysis from integrated bioinformatics and machine learning.","date":"2022","source":"Mathematical biosciences and engineering : MBE","url":"https://pubmed.ncbi.nlm.nih.gov/35341274","citation_count":3,"is_preprint":false},{"pmid":"27478449","id":"PMC_27478449","title":"Serum CETP and PLTP activity in middle-aged men living in urban or rural area of the Lower Silesia region. PURE Poland sub-study.","date":"2016","source":"Archives of medical science : AMS","url":"https://pubmed.ncbi.nlm.nih.gov/27478449","citation_count":3,"is_preprint":false},{"pmid":"21823416","id":"PMC_21823416","title":"[Study on the correlation between Chinese medical syndrome types and serum levels of PLTP and CETP in coronary heart disease patients].","date":"2011","source":"Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21823416","citation_count":1,"is_preprint":false},{"pmid":"41391040","id":"PMC_41391040","title":"Fibrates Inhibit PLTP-induced M2 Macrophage Infiltration and Increase the Sensitivity of Hepatocellular Carcinoma to ICIs.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41391040","citation_count":0,"is_preprint":false},{"pmid":"34385888","id":"PMC_34385888","title":"Association between the PLTP rs4810479 SNP and Serum Lipid Traits in the Chinese Maonan and Han Populations.","date":"2021","source":"Genetics research","url":"https://pubmed.ncbi.nlm.nih.gov/34385888","citation_count":0,"is_preprint":false},{"pmid":"42074254","id":"PMC_42074254","title":"Phospholipid Transfer Protein (PLTP) in Cholesterol Handling: Implications for Mitochondrial Lipid Homeostasis in Human iPSC-Derived Cardiomyocytes.","date":"2026","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/42074254","citation_count":0,"is_preprint":false},{"pmid":"39765303","id":"PMC_39765303","title":"Association of phospholipid transfer protein (PLTP) and the effect of genetic variant rs5072 on hypertriglyceridemia and atherogenic dyslipidemia in children and adolescents from Southeastern Mexico.","date":"2025","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39765303","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.11.21.25340771","title":"A sex-specific genome-wide association study of blood lipid levels in All of Us","date":"2025-11-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.21.25340771","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48200,"output_tokens":7504,"usd":0.12858,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17027,"output_tokens":7429,"usd":0.13543,"stage2_stop_reason":"end_turn"},"total_usd":0.26401,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Recombinant human and mouse PLTP expressed in BHK cells possesses both phospholipid transfer activity and HDL conversion activity, converting two distinct HDL subspecies (Lp(A-I) and Lp(A-I/A-II)) into larger and smaller particles in vitro.\",\n      \"method\": \"Eukaryotic cell expression of cDNA (BHK cells), in vitro HDL conversion assay with purified plasma-derived and recombinant PLTP\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution of both phospholipid transfer and HDL conversion with recombinant protein, replicated with plasma-derived PLTP\",\n      \"pmids\": [\"7654777\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PLTP binds to both apolipoprotein A-I and apoA-II; the PLTP-binding domain on apoA-I resides in the amino-terminal region (amino acids 27–141), as demonstrated by solid-phase ligand binding, ELISA displacement, and inhibition with anti-apoA-I monoclonal antibodies.\",\n      \"method\": \"Solid-phase ligand binding assay, ELISA with truncated recombinant apoA-I forms, apoA-I/apoA-II affinity chromatography, monoclonal antibody epitope mapping\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (affinity chromatography, ELISA, antibody inhibition) in a single focused study\",\n      \"pmids\": [\"9469594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Structure of PLTP was modeled on the BPI X-ray structure, predicting a two-domain architecture with conserved lipid-binding pockets. Site-directed mutagenesis of N-terminal pocket residues abolished phospholipid transfer activity without impairing HDL binding, while C-terminal pocket mutations affected HDL association. A disulfide bridge between Cys146 and Cys185 is essential for structural integrity.\",\n      \"method\": \"Molecular modeling based on BPI X-ray structure, site-directed mutagenesis, transient expression in HeLa cells, phospholipid transfer activity assay, solid-phase HDL-binding assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis combined with functional assay and binding assay; multiple mutants tested in a single rigorous study\",\n      \"pmids\": [\"10357844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PLTP has an inherent serine esterase-type protease activity: incubation with HDL3 or purified apoA-I causes proteolytic cleavage of apoA-I between residues Ala196 and Thr197 (generating a 23 kDa C-terminal fragment), inhibitable by APMSF and chymostatin. This activity was reproduced with recombinant PLTP from CHO and baculovirus systems.\",\n      \"method\": \"SDS-PAGE, Western blot, mass spectrometry, N-terminal sequencing, protease inhibitor experiments, in vitro incubation assay with purified plasma and recombinant PLTP\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — enzymatic activity confirmed by multiple methods (mass spec, sequencing, inhibitor profiling) with both plasma-derived and recombinant PLTP\",\n      \"pmids\": [\"10191289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Phospholipid transfer is a prerequisite for PLTP-mediated HDL conversion: chemical modification of PLTP that reduces phospholipid transfer activity in parallel reduces HDL conversion; recombinant PLTP mutants defective in N-terminal lipid-binding pocket activity are unable to release apoA-I from HDL3 or generate prebeta-HDL particles.\",\n      \"method\": \"Chemical modification (DEPC, ethylmercurithiosalicylate), recombinant mutant protein production, native gradient gel electrophoresis, ultracentrifugation, crossed immunoelectrophoresis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — three independent analytical methods plus chemical modification and site-directed mutants establish causal link between transfer activity and HDL conversion\",\n      \"pmids\": [\"11123937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Two forms of PLTP exist in human plasma: a high-activity form (HA-PLTP, ~160 kDa) associated with apoE but not apoA-I, and a low-activity form (LA-PLTP, ~520 kDa) complexed with apoA-I. LA-PLTP shows higher affinity for heparin-Sepharose than HA-PLTP; the model proposed is that nascent PLTP enters circulation as HA-PLTP and is transferred to apoA-I-containing HDL, becoming the LA-PLTP complex.\",\n      \"method\": \"Heparin-Sepharose chromatography, hydrophobic interaction chromatography, anti-PLTP immunoaffinity chromatography, hydroxylapatite chromatography, SDS-PAGE, Western blot, immunoprecipitation, gel filtration\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal biochemical fractionation and immunochemical methods in a single dedicated study\",\n      \"pmids\": [\"11854286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PLTP is a direct transcriptional target of liver X receptor (LXR): LXR ligands induce PLTP 6-fold in murine and human macrophages, and two functional LXR response elements (one classic DR4, one novel IR1 identical to FXR response element) were identified and characterized in the proximal PLTP promoter.\",\n      \"method\": \"Affymetrix microarray, Northern blot, luciferase reporter assay with LXR response element mutations\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional LXRE characterized by mutagenesis in reporter assays, validated by Northern blot across two cell types\",\n      \"pmids\": [\"12454263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PLTP secreted by HepG2 hepatoma cells co-elutes with apolipoprotein E (apoE) by size-exclusion chromatography and is retained on anti-apoE immunoaffinity columns; anti-apoE antibodies inhibit PLTP activity, indicating a functional interaction between PLTP and apoE in the high-activity form.\",\n      \"method\": \"Heparin-Sepharose affinity chromatography, size-exclusion chromatography, anti-apoE immunoaffinity chromatography, PLTP activity assay, antibody inhibition\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal immunoaffinity plus antibody inhibition of activity, multiple orthogonal methods\",\n      \"pmids\": [\"12810820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Mast cell chymase proteolytically degrades PLTP into fragments (70, 52, 48, and 31 kDa), reducing its phospholipid transfer activity and ability to generate prebeta-HDL. Chymase also degrades pre-beta-HDL particles generated by PLTP, significantly inhibiting the high-affinity component of cholesterol efflux from macrophage foam cells.\",\n      \"method\": \"Immunoblot, in vitro chymase cleavage assay, phospholipid transfer activity assay, cholesterol efflux assay from macrophage foam cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro enzymatic cleavage mapped by immunoblot, functional consequences confirmed by activity assay and cholesterol efflux assay\",\n      \"pmids\": [\"12531890\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PLTP functions as a transfer factor for alpha-tocopherol (vitamin E) in the brain: PLTP-deficient mice show significant brain alpha-tocopherol depletion (-30%), accompanied by elevated lipofuscin, cholesterol oxides, and cellular peroxides, and increased anxiety behavior.\",\n      \"method\": \"PLTP knockout mouse model, alpha-tocopherol quantification, lipid peroxide assays, elevated plus-maze behavioral test\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function with multiple biochemical and behavioral readouts, dose-dependent in hetero- and homozygotes\",\n      \"pmids\": [\"15576481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PLTP is synthesized and secreted as an active protein by neurons, microglia, and astrocytes in culture; exogenous recombinant PLTP added to primary human astrocytes significantly increases apoE secretion into conditioned medium, linking PLTP activity to apoE metabolism in the CNS.\",\n      \"method\": \"Western blot, phospholipid transfer activity assay in cell-conditioned medium, PLTP immunohistochemistry, exogenous recombinant PLTP addition to astrocyte cultures, apoE ELISA\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct functional experiment (recombinant PLTP → apoE secretion) in a single lab with single cellular readout\",\n      \"pmids\": [\"15795933\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Phospholipid transfer activity of PLTP is essential for its atherogenic effects: mice expressing a transfer-inactive PLTP mutant (still able to associate with HDL) show no changes in HDL lipid levels, no stimulation of hepatic VLDL-TG secretion, and no increase in atherosclerotic lesion size, unlike mice expressing active PLTP.\",\n      \"method\": \"Transgenic mouse model expressing mutant PLTP (transfer-inactive), cholesterol-enriched diet atherosclerosis model, plasma lipid assays, hepatic VLDL secretion assay\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via mutagenesis in vivo, multiple metabolic and atherosclerosis endpoints compared between active and inactive transgene\",\n      \"pmids\": [\"18711210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Acute elevation of plasma PLTP activity in LDL receptor knockout mice inhibits VLDL catabolism (at least partly by decreasing lipoprotein lipase activity), increases plasma VLDL levels, decreases HDL, and accelerates progression and destabilization of pre-existing atherosclerotic lesions.\",\n      \"method\": \"Conditional tetracycline-inducible PLTP transgenic mouse model, plasma lipid assays, VLDL secretion assay, lipoprotein lipase activity assay, atherosclerosis lesion analysis\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — inducible genetic model with multiple mechanistic readouts; lipoprotein lipase activity identified as downstream mechanism\",\n      \"pmids\": [\"18421000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PLTP localizes to the nucleus of cells that constitutively express it and of PLTP-transfected cells; nuclear export of PLTP is CRM1-dependent (blocked by leptomycin B); secreted extracellular PLTP can re-enter cells and translocate to the nucleus; intranuclear PLTP retains phospholipid transfer activity.\",\n      \"method\": \"Subcellular fractionation, leptomycin B treatment, live-cell imaging, phospholipid transfer activity assay of nuclear fractions, transfection of CHO/BHK cells\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct localization experiment with functional consequence (nuclear PLTP is active), single lab\",\n      \"pmids\": [\"19321130\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PLTP activates the STAT3 anti-inflammatory pathway in macrophages via ABCA1: incubation with wild-type PLTP or a lipid-transfer-inactive PLTP mutant (M159E) both increase nuclear pSTAT3(Tyr705), and this effect is reversed by ABCA1 chemical inhibition (glyburide) or ABCA1 siRNA knockdown. PLTP also reduces nuclear NFκB p65 levels and pro-inflammatory cytokine secretion.\",\n      \"method\": \"Nuclear fractionation, Western blot for pSTAT3 and NFκB p65, ELISA for cytokines, ABCA1 inhibitor, ABCA1 siRNA, lipid-transfer-inactive PLTP mutant, differentiated THP1 cells and primary human macrophages\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic (siRNA) and pharmacological ABCA1 inhibition, inactive PLTP mutant used to dissociate lipid transfer from signaling, multiple orthogonal readouts\",\n      \"pmids\": [\"21782857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Liver-specific PLTP expression (in PLTP-null background) dramatically increases plasma VLDL levels (non-HDL cholesterol 2.7-fold, apoB 2.2-fold) by increasing VLDL lipidation in hepatocyte microsomal lumina and VLDL secretion, without significantly affecting HDL.\",\n      \"method\": \"Adenovirus-mediated liver-specific PLTP expression in PLTP-null mice, VLDL secretion assay, hepatocyte microsomal lipidation assay, plasma lipoprotein profiling\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific rescue experiment with mechanistic readout (microsomal lipidation assay), clean PLTP-null background\",\n      \"pmids\": [\"22367708\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PLTP deficiency impairs blood-brain barrier integrity by increasing cerebrovascular oxidative stress (elevated ROS, 4-HNE, reduced SOD activity), leading to decreased expression of tight junction proteins occludin, ZO-1, and claudin-5; dietary vitamin E supplementation rescues BBB integrity, placing PLTP's vitamin E transfer activity upstream of BBB maintenance.\",\n      \"method\": \"PLTP knockout mice, in vivo multiphoton imaging, Evans blue assay, Western blot for tight junction proteins, ROS/lipid peroxidation assays, vitamin E dietary rescue\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic KO with multiple BBB readouts and mechanistic rescue by vitamin E, single lab\",\n      \"pmids\": [\"24513285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cathepsin G (a serine protease) cleaves and inactivates PLTP in the lung: PLTP activity in COPD bronchoalveolar lavage is reduced 80% due to cathepsin G-mediated degradation. PLTP siRNA silencing in mouse lungs increases ERK/NF-κB activation and inflammatory cell infiltration after LPS challenge, while recombinant PLTP protein counters these effects.\",\n      \"method\": \"Proteolytic cleavage assay, PLTP activity assay in BALF, PLTP siRNA in mouse lung (LPS model), recombinant PLTP administration, Western blot for ERK/NF-κB, ELISA for cytokines\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protease identified biochemically, complementary gain-and-loss-of-function in vivo with multiple inflammatory readouts\",\n      \"pmids\": [\"24532668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PLTP deficiency in an APP/PS1 Alzheimer's model accelerates memory dysfunction and increases Aβ peptides by enhancing the amyloidogenic APP processing pathway (increased β- and γ-secretase activity), and reduces BDNF levels; autophagic dysfunction is also observed in PLTP-deficient AD model mice.\",\n      \"method\": \"PLTP KO × APP/PS1ΔE9 double-mutant mice, Morris water maze, ELISA for Aβ40/42, Western blot for APP/secretase subunits, secretase activity assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic double-mutant model with mechanistic enzyme activity readout, single lab\",\n      \"pmids\": [\"26160914\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Electron microscopy reveals PLTP has a banana-shaped structure similar to CETP; PLTP penetrates into both HDL and LDL surfaces and forms a ternary PLTP–HDL–LDL complex, providing a structural basis for its phospholipid transfer mechanism between lipoproteins.\",\n      \"method\": \"Negative-stain electron microscopy, cryo-EM, single-particle analysis, ternary complex reconstitution\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — structural EM with reconstituted ternary complex, single lab without mutagenesis validation\",\n      \"pmids\": [\"29883800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In rheumatoid arthritis fibroblast-like synoviocytes (FLS), both lipid-transfer-active and lipid-transfer-inactive recombinant PLTP increase pro-inflammatory cytokine production (IL-8, IL-6, VEGF, MMP3) and cell proliferation, and activate the STAT3 pathway via ABCA1; this pro-inflammatory effect is independent of PLTP's lipid transfer activity.\",\n      \"method\": \"Recombinant active and inactive PLTP treatment of FLS, ELISA for cytokines, [3H]-thymidine proliferation assay, ABCA1 flow cytometry, STAT3 Western blot\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — lipid-transfer-inactive PLTP mutant used to dissociate mechanism, multiple cytokine readouts; single lab\",\n      \"pmids\": [\"29565987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PLTP deficiency protects mice from high-fat-diet-induced obesity and insulin resistance by enhancing insulin receptor and Akt phosphorylation in liver, adipose, and muscle; PLTP-deficient cells show increased GLUT4 at plasma membranes after insulin stimulation; mechanistically, PLTP deficiency reduces sphingomyelin and free cholesterol content in lipid rafts/plasma membranes, providing a molecular basis for improved insulin sensitivity.\",\n      \"method\": \"PLTP knockout mouse model, high-fat diet, glucose/insulin tolerance tests, Western blot for p-IR/p-Akt, plasma membrane GLUT4 fractionation, lipid raft lipid composition analysis\",\n      \"journal\": \"Biochimica et biophysica acta. Molecular and cell biology of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic KO with mechanistic lipid raft composition readout linking PLTP to membrane cholesterol and insulin signaling; single lab\",\n      \"pmids\": [\"31220615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PLTP is a batokine secreted by brown adipose tissue (BAT): proteomics/transcriptomics in human thermogenic adipocytes identified PLTP; BAT-specific or systemic PLTP overexpression improves glucose tolerance and insulin sensitivity, increases energy expenditure, and reduces circulating cholesterol/phospholipids/sphingolipids. These effects are mediated by increased circulating bile acids, which enhance glucose uptake and thermogenesis in BAT.\",\n      \"method\": \"Proteomics and transcriptomics in human thermogenic adipocytes, BAT-specific and systemic PLTP overexpression in mice, glucose/insulin tolerance tests, bile acid measurements, energy expenditure measurements\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific overexpression identifies BAT as PLTP source; bile acid pathway proposed as mediator with supporting measurements, single lab\",\n      \"pmids\": [\"32672883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PLTP is a p53 transcriptional target gene: three cancer-associated hypomorphic p53 variants show impaired PLTP transactivation by RNA-seq; enforced PLTP expression suppresses colony formation in human tumor cell lines and regulates ferroptosis sensitivity.\",\n      \"method\": \"RNA-seq in lymphoblastoid cell lines with p53 hypomorphs, colony formation assay with PLTP overexpression, ferroptosis sensitivity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — transcriptional regulation by p53 confirmed by RNA-seq and functional overexpression; ferroptosis role demonstrated by single assay; single lab\",\n      \"pmids\": [\"36309086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PLTP promotes M2 macrophage polarization in hepatocellular carcinoma by binding to aurora kinase A (AURKA) and p65, forming a ternary complex that induces p65 phosphorylation and activates NF-κB, upregulating IL-6, IL-8, and CSF-1; the PLTP inhibitor GMB-475 (binding PLTP's 25–245 AA domain) competitively disrupts this complex and reduces M2 infiltration in vivo.\",\n      \"method\": \"Co-immunoprecipitation, molecular docking, proteomics, Western blot for p-p65/NF-κB targets, ELISA for cytokines, GMB-475 treatment in orthotopic and Myc-driven HCC mouse models\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-IP identifies PLTP–AURKA–p65 complex; GMB-475 functional validation in vivo; single lab, preliminary mechanistic detail\",\n      \"pmids\": [\"41391040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In diabetic retinopathy, DNMT3B-mediated DNA hypermethylation of the PLTP promoter suppresses PLTP expression; PLTP overexpression reverses high-glucose-induced impairment of endothelial cell migration and tube formation, and promotes AKT and GSK3β phosphorylation, placing PLTP upstream of the AKT/GSK3β signaling pathway in retinal vascular function.\",\n      \"method\": \"siRNA knockdown of DNMT3B, luciferase reporter assay, co-immunoprecipitation, transcriptome sequencing, GSK3β inhibitor, tube formation and migration assays in HRMECs, streptozotocin mouse model\",\n      \"journal\": \"Clinical epigenetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — DNMT3B identified as methylation writer by siRNA + reporter assay; PLTP-AKT/GSK3β pathway validated by multiple functional assays; single lab\",\n      \"pmids\": [\"40380281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ApoA-I (and also apoE, apoA-II, apoA-IV but not immunoglobulins or BSA) enhances the phospholipid transfer activity of PLTP secreted from macrophage foam cells without affecting PLTP mass or secretion; apoA-I also protects PLTP from heat inactivation.\",\n      \"method\": \"THP-1 monocyte-derived macrophage foam cell model, PLTP activity assay in conditioned medium, PLTP ELISA, incubation with purified apolipoproteins and plasma-derived PLTP\",\n      \"journal\": \"Lipids in health and disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct in vitro biochemical experiment with isolated components; apolipoprotein specificity tested with multiple controls; single lab\",\n      \"pmids\": [\"20534134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In vivo tracer/mass spectrometry studies show PLTP is secreted associated with medium and large HDL (alpha2, alpha1, alpha0) and is transferred from medium to larger HDL sizes during circulation, from which it is catabolized; this metabolic behavior is distinct from CETP and LCAT.\",\n      \"method\": \"In vivo stable-isotope tracer infusion, targeted mass spectrometry (Orbitrap Lumos), compartmental modeling across multiple HDL sizes in 6 human participants\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vivo human tracer study with compartmental modeling; small n=6; single lab but novel direct measurement of PLTP metabolism on HDL\",\n      \"pmids\": [\"33351780\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PLTP is a secreted lipid-transfer glycoprotein with a two-domain, banana-shaped structure (modeled on BPI; confirmed by EM) that mediates phospholipid transfer between lipoproteins and remodels HDL by a mechanism requiring its N-terminal lipid-binding pocket and forming a transient PLTP–HDL–LDL ternary complex; phospholipid transfer is a prerequisite for HDL conversion and prebeta-HDL generation. PLTP circulates in two forms—a high-activity ~160 kDa complex associated with apoE and a low-activity ~520 kDa complex bound to apoA-I—and binds apoA-I at its N-terminal region (residues 27–141). Beyond lipid transfer, PLTP transfers alpha-tocopherol (vitamin E) to the brain and across the blood-brain barrier, transfers LPS to HDL for detoxification, and exerts ABCA1-dependent anti-inflammatory signaling in macrophages (activating STAT3, suppressing NF-κB) independent of its lipid transfer activity. PLTP is a direct LXR and p53 transcriptional target, undergoes CRM1-dependent nuclear export (with active intranuclear PLTP), and is cleaved/inactivated by cathepsin G and mast cell chymase. In the liver, PLTP drives VLDL lipidation and secretion; in brown adipose tissue it functions as a batokine that promotes bile acid-mediated glucose homeostasis; and in cancer cells it promotes M2 macrophage polarization via an AURKA–p65–NF-κB complex and suppresses tumor growth as a p53 target involved in ferroptosis regulation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PLTP is a secreted lipid-transfer glycoprotein that remodels HDL and broadly governs plasma lipoprotein metabolism, transferring phospholipids between lipoproteins and converting HDL into larger and smaller subspecies while generating prebeta-HDL [#0]. Structurally it adopts a two-domain, banana-shaped architecture modeled on BPI and visualized by electron microscopy, with an N-terminal lipid-binding pocket that executes transfer and a C-terminal pocket that mediates HDL association; an intramolecular disulfide (Cys146-Cys185) is required for structural integrity, and PLTP penetrates both HDL and LDL surfaces to form a transient ternary PLTP-HDL-LDL complex [#2, #19]. Phospholipid transfer is the obligate step driving HDL conversion and prebeta-HDL formation, as transfer-inactive mutants fail to release apoA-I or generate prebeta-HDL [#4]. In plasma PLTP circulates as a high-activity ~160 kDa form associated with apoE and a low-activity ~520 kDa form complexed with apoA-I, binding apoA-I through its amino-terminal residues 27-141 [#1, #5, #7]. The transfer activity is causally required for PLTP's metabolic effects in vivo: active PLTP stimulates hepatic VLDL lipidation and secretion and promotes atherosclerosis, whereas transfer-inactive PLTP does not [#11, #15]. Beyond lipid transfer, PLTP delivers alpha-tocopherol (vitamin E) to the brain, where its loss depletes brain vitamin E and compromises blood-brain barrier integrity through oxidative stress [#9, #16]. PLTP also exerts a lipid-transfer-independent, ABCA1-dependent anti-inflammatory program in macrophages, activating STAT3 and suppressing NF-kappaB [#14]. Its expression is transcriptionally controlled, being a direct LXR and p53 target gene [#6, #23], and its activity is post-translationally limited by proteolytic inactivation through cathepsin G and mast cell chymase [#8, #17]. More recent work links PLTP to brown adipose tissue as a glucose-regulating batokine [#22] and to tumor biology as a p53-responsive suppressor and modulator of macrophage polarization [#23, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing that a single recombinant protein carries both phospholipid transfer and HDL conversion activity defined PLTP as the enzyme responsible for HDL particle remodeling.\",\n      \"evidence\": \"Recombinant human/mouse PLTP expressed in BHK cells, in vitro HDL conversion assays\",\n      \"pmids\": [\"7654777\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether the two activities are mechanistically coupled\", \"No structural basis for activity\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Mapping the apoA-I binding determinant to its N-terminal region (aa 27-141) identified the molecular contacts through which PLTP docks onto HDL apolipoproteins.\",\n      \"evidence\": \"Solid-phase ligand binding, ELISA with truncated apoA-I, antibody epitope mapping\",\n      \"pmids\": [\"9469594\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the reciprocal PLTP surface engaging apoA-I\", \"Functional consequence of binding not yet linked to transfer\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"A BPI-based structural model plus mutagenesis resolved the division of labor between the N-terminal transfer pocket and C-terminal HDL-binding pocket and identified an essential stabilizing disulfide.\",\n      \"evidence\": \"Molecular modeling on BPI X-ray structure, site-directed mutagenesis, transient HeLa expression with transfer and HDL-binding assays\",\n      \"pmids\": [\"10357844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Model not validated by direct PLTP structure determination\", \"Catalytic mechanism of transfer unresolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Detection of an intrinsic serine-esterase protease activity cleaving apoA-I raised the possibility that PLTP acts on lipoproteins beyond lipid transfer.\",\n      \"evidence\": \"SDS-PAGE, mass spectrometry, N-terminal sequencing, inhibitor profiling with plasma and recombinant PLTP\",\n      \"pmids\": [\"10191289\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological relevance of the protease activity not established\", \"Not reconciled with lipid-transfer mechanism\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Showing that abolishing phospholipid transfer abolishes HDL conversion established transfer as the obligatory upstream step for prebeta-HDL generation.\",\n      \"evidence\": \"Chemical modification and N-terminal pocket mutants, native gel electrophoresis, ultracentrifugation, crossed immunoelectrophoresis\",\n      \"pmids\": [\"11123937\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address transfer-independent functions later identified\", \"In vitro only\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Resolving plasma PLTP into apoE-associated high-activity and apoA-I-associated low-activity forms explained the heterogeneity of circulating PLTP activity.\",\n      \"evidence\": \"Multimodal chromatography, immunoprecipitation, gel filtration of human plasma\",\n      \"pmids\": [\"11854286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism converting HA-PLTP to LA-PLTP inferred, not directly demonstrated\", \"Structural basis of activity difference unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of functional LXR response elements in the PLTP promoter placed PLTP under sterol-sensing transcriptional control in macrophages.\",\n      \"evidence\": \"Microarray, Northern blot, luciferase reporter assays with LXRE mutagenesis in murine and human macrophages\",\n      \"pmids\": [\"12454263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of LXR control to plasma PLTP not quantified\", \"Other transcriptional inputs not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating apoE association of secreted PLTP and inhibition of activity by anti-apoE antibodies identified apoE as a functional partner of the high-activity form.\",\n      \"evidence\": \"HepG2 conditioned medium, anti-apoE immunoaffinity chromatography, antibody inhibition of activity\",\n      \"pmids\": [\"12810820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and binding interface with apoE undefined\", \"How apoE enhances activity unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mast cell chymase degradation of PLTP and prebeta-HDL revealed a proteolytic mechanism limiting PLTP-driven cholesterol efflux.\",\n      \"evidence\": \"In vitro chymase cleavage, immunoblot fragment mapping, transfer activity and macrophage foam cell cholesterol efflux assays\",\n      \"pmids\": [\"12531890\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution of chymase to PLTP turnover not established\", \"Cleavage sites not mapped\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"PLTP knockout mice with depleted brain vitamin E and oxidative damage extended PLTP function to alpha-tocopherol delivery in the CNS.\",\n      \"evidence\": \"PLTP KO mice, alpha-tocopherol and lipid peroxide quantification, behavioral testing\",\n      \"pmids\": [\"15576481\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of tocopherol transfer not dissected\", \"Tissue route of delivery not defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating PLTP secretion by CNS cells and its stimulation of astrocyte apoE secretion linked PLTP to brain lipoprotein metabolism.\",\n      \"evidence\": \"Western blot, activity assays in conditioned medium, immunohistochemistry, exogenous PLTP addition with apoE ELISA\",\n      \"pmids\": [\"15795933\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single readout in one lab\", \"Mechanism by which PLTP increases apoE secretion unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Transgenic expression of transfer-inactive PLTP showed lipid transfer is necessary for PLTP's effects on HDL, VLDL secretion, and atherosclerosis in vivo.\",\n      \"evidence\": \"Transgenic mice expressing transfer-inactive PLTP, atherosclerosis diet model, plasma lipid and hepatic VLDL assays\",\n      \"pmids\": [\"18711210\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address transfer-independent signaling functions\", \"Mechanism of VLDL stimulation not yet localized to hepatocyte\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Acute PLTP elevation worsening lipoprotein profiles via reduced lipoprotein lipase activity identified a downstream metabolic mechanism for PLTP's atherogenicity.\",\n      \"evidence\": \"Inducible PLTP transgenic LDLR-KO mice, VLDL secretion, lipoprotein lipase activity, lesion analysis\",\n      \"pmids\": [\"18421000\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How PLTP reduces LPL activity unresolved\", \"Reversibility not tested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery of CRM1-dependent nuclear export and active intranuclear PLTP raised the prospect of a non-secretory intracellular role.\",\n      \"evidence\": \"Subcellular fractionation, leptomycin B, live imaging, activity assay of nuclear fractions\",\n      \"pmids\": [\"19321130\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Nuclear substrates or functions not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Using a lipid-transfer-inactive mutant and ABCA1 loss-of-function established a transfer-independent anti-inflammatory STAT3/NF-kappaB signaling function in macrophages.\",\n      \"evidence\": \"Nuclear fractionation/Western blot, ABCA1 siRNA and glyburide, inactive PLTP mutant in THP1 and primary macrophages\",\n      \"pmids\": [\"21782857\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct PLTP-ABCA1 interaction not demonstrated\", \"Receptor-level mechanism of STAT3 activation unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Liver-specific PLTP expression localized the VLDL-stimulating activity to hepatocyte microsomal lipidation, defining PLTP's role in VLDL assembly.\",\n      \"evidence\": \"Adenoviral liver-specific PLTP in PLTP-null mice, microsomal lipidation and VLDL secretion assays\",\n      \"pmids\": [\"22367708\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular site of PLTP action within the secretory pathway not pinpointed\", \"Relationship to circulating PLTP unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating apolipoprotein-specific enhancement of PLTP activity clarified how HDL apolipoproteins modulate and stabilize secreted PLTP.\",\n      \"evidence\": \"THP-1 foam cell conditioned medium, activity assays and heat-inactivation protection with purified apolipoproteins\",\n      \"pmids\": [\"20534134\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of activity enhancement not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Linking PLTP loss to BBB breakdown reversible by vitamin E placed PLTP's tocopherol transfer upstream of cerebrovascular integrity.\",\n      \"evidence\": \"PLTP KO mice, multiphoton imaging, Evans blue, tight junction Western blots, vitamin E rescue\",\n      \"pmids\": [\"24513285\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cellular target of oxidative stress not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying cathepsin G as a PLTP-inactivating protease in lung and showing PLTP restrains LPS-induced inflammation extended proteolytic regulation and anti-inflammatory roles to the airway.\",\n      \"evidence\": \"Proteolytic cleavage assays, BALF activity, lung PLTP siRNA and recombinant PLTP in LPS model with ERK/NF-kappaB readouts\",\n      \"pmids\": [\"24532668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cleavage sites not mapped\", \"Relationship to chymase-mediated cleavage not compared\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"PLTP deficiency accelerating amyloid pathology in an Alzheimer's model implicated PLTP in APP processing and neuronal homeostasis.\",\n      \"evidence\": \"PLTP KO x APP/PS1 mice, behavioral tests, Abeta ELISA, secretase activity assays\",\n      \"pmids\": [\"26160914\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting PLTP to secretase activity unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Electron microscopy of PLTP and a reconstituted ternary complex provided the structural basis for inter-lipoprotein phospholipid transfer.\",\n      \"evidence\": \"Negative-stain and cryo-EM single-particle analysis, ternary PLTP-HDL-LDL complex reconstitution\",\n      \"pmids\": [\"29883800\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No atomic-resolution structure or mutagenesis validation\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showing transfer-independent pro-inflammatory STAT3/ABCA1 signaling in synoviocytes generalized PLTP's signaling function beyond macrophages and beyond a purely protective role.\",\n      \"evidence\": \"Active and inactive recombinant PLTP on fibroblast-like synoviocytes, cytokine ELISA, proliferation and STAT3 assays\",\n      \"pmids\": [\"29565987\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Context-dependence of pro- vs anti-inflammatory STAT3 outcome unexplained\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"PLTP deficiency improving insulin sensitivity via reduced membrane sphingomyelin/cholesterol linked PLTP to lipid raft composition and insulin signaling.\",\n      \"evidence\": \"PLTP KO mice on high-fat diet, glucose/insulin tests, p-IR/p-Akt and GLUT4 fractionation, lipid raft composition analysis\",\n      \"pmids\": [\"31220615\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PLTP action on membrane lipids not demonstrated in situ\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying PLTP as a brown adipose batokine acting through circulating bile acids defined a new endocrine role in glucose homeostasis and thermogenesis.\",\n      \"evidence\": \"Human thermogenic adipocyte proteomics/transcriptomics, BAT-specific and systemic PLTP overexpression, glucose/bile acid/energy expenditure measurements\",\n      \"pmids\": [\"32672883\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which PLTP raises bile acids unresolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Human in vivo tracer studies established that PLTP is secreted on medium/large HDL and follows a catabolic route distinct from CETP and LCAT.\",\n      \"evidence\": \"Stable-isotope tracer infusion, targeted mass spectrometry and compartmental modeling in 6 participants\",\n      \"pmids\": [\"33351780\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Small sample size\", \"Molecular determinants of HDL-size association not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Establishing PLTP as a p53 transcriptional target with tumor-suppressive and ferroptosis-modulating activity connected PLTP to the p53 stress-response network.\",\n      \"evidence\": \"RNA-seq in p53-hypomorph lymphoblastoid lines, colony formation and ferroptosis assays with PLTP overexpression\",\n      \"pmids\": [\"36309086\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking PLTP to ferroptosis not defined\", \"Single ferroptosis assay\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identifying a PLTP-AURKA-p65 complex driving NF-kappaB-dependent M2 macrophage polarization revealed a protein-protein-interaction mechanism in hepatocellular carcinoma.\",\n      \"evidence\": \"Co-IP, docking, proteomics, p-p65 Western blots, cytokine ELISA, GMB-475 inhibitor in orthotopic and Myc-driven HCC models\",\n      \"pmids\": [\"41391040\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reciprocal validation and binding interface incompletely defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showing DNMT3B-mediated promoter hypermethylation silences PLTP and that PLTP drives AKT/GSK3beta signaling defined epigenetic control and a vascular signaling axis in diabetic retinopathy.\",\n      \"evidence\": \"DNMT3B siRNA, luciferase reporter, co-IP, transcriptomics, migration/tube formation assays in HRMECs, STZ mouse model\",\n      \"pmids\": [\"40380281\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PLTP receptor/effector for AKT activation unidentified\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PLTP's lipid-transfer-independent signaling functions are physically transduced — including the receptor or membrane events linking PLTP to ABCA1/STAT3, the basis of intranuclear activity, and the determinants of its context-dependent pro- versus anti-inflammatory output — remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined receptor for PLTP signaling\", \"Nuclear function and substrates undefined\", \"Atomic-resolution structure with mutational validation lacking\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [0, 4, 19]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 9, 19]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [14, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 5, 7, 27]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 11, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [14, 17, 20, 24]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 24, 25]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 23, 25]}\n    ],\n    \"complexes\": [\n      \"PLTP-HDL-LDL ternary complex\",\n      \"PLTP-AURKA-p65 complex\",\n      \"high-activity PLTP-apoE complex\",\n      \"low-activity PLTP-apoA-I complex\"\n    ],\n    \"partners\": [\n      \"APOA1\",\n      \"APOE\",\n      \"APOA2\",\n      \"ABCA1\",\n      \"AURKA\",\n      \"RELA\",\n      \"STAT3\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":9,"faith_pct":88.88888888888889}}